What the business is, and whether it's a good one at a fair price.
A Pharmaceuticals & Biotechnology company listed on NSE and BSE, reporting revenue of ₹138 Cr over the trailing twelve months.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from LYKA LABS LTD.'s filed financials and exchange disclosures
LYKA LABS LTD. is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol LYKALABS.
No. Over the trailing twelve months LYKA LABS LTD. reported a net loss of ₹9 Cr on revenue of ₹138 Cr.
Not in the latest reported year — LYKA LABS LTD.'s dividend payout for FY26 was nil.
No. Debt stands at 0.53× equity, and it carries net debt of ₹47 Cr. That is lower than 15% of its 171 Pharmaceuticals peers.
On a typical session LYKA LABS LTD. moves 1.53% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by LYKA LABS LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
